제일약품

271980KOSPI의약품 제조업

60.4 / 100

Reference Date: 2026-06-10

Financial Score26.5 / 40

News Sentiment19.9 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue is on a declining trend. Plunged 25.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharm was established in 2017 through a spin-off from Jeil Pharma Holdings, focusing on the manufacturing and sales of finished pharmaceutical products. Its subsidiary, Oncol Therapeutics, specializes in new drug development. Key products include treatments for hypercholesterolemia, hyperlipidemia, and gastric cancer, with major revenue contributors being Lipito tablets and Lyrica capsules.

Number of Employees

1,011people

Average Salary

63.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

4.68Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR

0.60Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

13.61Industry Average 4.017.0Point

3.4x industry avg (excellent)

Debt Ratio

6.81Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼53.7% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.3% (improving, 3yr)

Detailed News Sentiment

15 totalPositive 13Neutral 2Negative 0Average Sentiment Score 79.7

Positive
케이캡 독주 속 자큐보 반란…국산 P-CAB 3파전, 판도 바뀌나
제일약품의 자큐보가 케이캡을 제치고 처방액 2위를 기록하며 국산 P-CAB 시장에서의 경쟁력을 강화하고 있다.
Positive
동아에스티 "'자큐보정' 국내 P-CAB 시장 2위 등극"
동의약품의 자큐보정이 국내 P-CAB 시장에서 2위를 차지하며 경쟁력을 강화했다.
Positive
자큐보, 국내 P-CAB 시장 2위…동아에스티·제일약품 공동 판매 효...
제일약품과 동아에스티의 공동 판매로 자큐보의 국내 P-CAB 시장 점유율이 확대되어 매출이 증가했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 10,180Won52-week high 17,39052-week low 10,180

1-month return0.0Point

1m -25.15% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral[기재정정]분기보고서 (2026.03)2026-05-18
Neutral분기보고서 (2026.03)2026-05-15